 |
|
When Is a New Prediction Marker Useful?
A Consideration of Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Stroke Risk
Arch Intern Med. 2005;165:2454-2456.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Ischemic stroke is a common and often devastating condition that can cause significant disability or death. In light of the dire consequences of a completed stroke, the search for improved predictive models and new markers to identify patients at heightened risk is well justified. Such high-risk patients would be candidates for proven stroke-prevention therapies including aspirin,1 antihypertensive medications, and HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors.2
Over the past several decades, multivariable models have been developed for prediction of coronary heart disease (CHD). A common approach to multivariate risk estimation for CHD is the Framingham Risk Score.3 This method uses readily available clinical data including the patient’s age, sex, blood pressure, blood cholesterol level, high-density lipoprotein cholesterol (HDL-C) level, smoking status, and diabetes status in a logistic regression model to estimate 10-year CHD event risk. While not perfect for CHD risk prediction, nonetheless the Framingham Risk Score markedly improves risk estimation . . . [Full Text of this Article]
AUTHOR INFORMATION
Philip Greenland, MD;
LTC Patrick G. O’Malley, MC, USA
RELATED LETTER
The Role of Inflammation for Heart Disease Risk Cannot Be Determined by Correlations Between C-Reactive Protein and Risk Factors—Reply
Michael Miller and Stephen Havas
Arch Intern Med. 2006;166(9):1040-1041.
EXTRACT
| FULL TEXT
RELATED ARTICLES
C-Reactive Protein and Risk of Cardiovascular Disease in Men and Women From the Framingham Heart Study
Peter W. F. Wilson, Byung-Ho Nam, Michael Pencina, Ralph B. D’Agostino, Sr, Emelia J. Benjamin, and Christopher J. O’Donnell
Arch Intern Med. 2005;165(21):2473-2478.
ABSTRACT
| FULL TEXT
Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study
Christie M. Ballantyne, Ron C. Hoogeveen, Heejung Bang, Josef Coresh, Aaron R. Folsom, Lloyd E. Chambless, Merle Myerson, Kenneth K. Wu, A. Richey Sharrett, and Eric Boerwinkle
Arch Intern Med. 2005;165(21):2479-2484.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Tumor Necrosis Factor-{alpha} and Mortality in Heart Failure: A Community Study
Dunlay et al.
Circulation 2008;118:625-631.
ABSTRACT
| FULL TEXT
New cardiovascular risk determinants do exist and are clinically useful
Smulders et al.
Eur Heart J 2008;29:436-440.
ABSTRACT
| FULL TEXT
High-Sensitivity C-Reactive Protein and Prediction of Nontraumatic Fractures
Cheng
Arch Intern Med 2007;167:2007-2007.
FULL TEXT
Letter by Janket et al Regarding Article, "Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction"
Janket et al.
Circulation 2007;116:e133-e133.
FULL TEXT
Association of Carotid Artery Intima-Media Thickness, Plaques, and C-Reactive Protein With Future Cardiovascular Disease and All-Cause Mortality: The Cardiovascular Health Study
Cao et al.
Circulation 2007;116:32-38.
ABSTRACT
| FULL TEXT
C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
Sattar et al.
Circulation 2007;115:981-989.
ABSTRACT
| FULL TEXT
Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction
Cook
Circulation 2007;115:928-935.
ABSTRACT
| FULL TEXT
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
Wang et al.
NEJM 2006;355:2631-2639.
ABSTRACT
| FULL TEXT
Lipoprotein-Associated Phospholipase A2 and Prognosis After Myocardial Infarction in the Community
Gerber et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:2517-2522.
ABSTRACT
| FULL TEXT
High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study
Bos et al.
Circulation 2006;114:1591-1598.
ABSTRACT
| FULL TEXT
Lp-PLA2: A New Kid on the Block
Zalewski et al.
Clin. Chem. 2006;52:1645-1650.
ABSTRACT
| FULL TEXT
Predicting cardiovascular risk: so what do we do now?
Lloyd-Jones and Tian
Arch Intern Med 2006;166:1342-1344.
FULL TEXT
C-reactive protein and cardiovascular risk in the framingham study.
Ridker et al.
Arch Intern Med 2006;166:1327-1328.
FULL TEXT
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan
Circulation 2006;113:2335-2362.
FULL TEXT
The Role of Inflammation for Heart Disease Risk Cannot Be Determined by Correlations Between C-Reactive Protein and Risk Factors--Reply
Miller and Havas
Arch Intern Med 2006;166:1040-1041.
FULL TEXT
The association between elevated levels of inflammation biomarkers and coronary artery disease and death.
Lowe
CMAJ 2006;174:479-480.
FULL TEXT
High sensitivity C-reactive protein in cardiovascular disease and type 2 diabetes: evidence for a clinical role?
Sattar
British Journal of Diabetes & Vascular Disease 2006;6:5-8.
|
